ReviewClinical pharmacokinetics1993
Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.
Review in Clinical pharmacokinetics, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.Drugs & aging · 2005Pooled it
- Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.European journal of clinical pharmacology · 2016Trial
- Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2005Trial
- Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.Antimicrobial agents and chemotherapy · 2001Trial
- Pharmacokinetics of isepamicin during continuous venovenous hemodiafiltration.Antimicrobial agents and chemotherapy · 1999Trial
- Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.Antimicrobial agents and chemotherapy · 1997Trial
- Exploring determinants in deciding the optimal antimicrobial dose in patients undergoing CRRT: a mixed-methods study.Antimicrobial agents and chemotherapy · 2025Article
- "CATCH" Study: Correct Antibiotic Therapy in Continuous Hemofiltration in the Critically Ill in Continuous Renal Replacement Therapy: A Prospective Observational Study.Antibiotics (Basel, Switzerland) · 2022Article
- Antibiotic Therapy in the Critically Ill with Acute Renal Failure and Renal Replacement Therapy: A Narrative Review.Antibiotics (Basel, Switzerland) · 2022Review
- Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.European journal of drug metabolism and pharmacokinetics · 2021Article
- Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy.Pharmaceutical research · 2020Article
- Antiepileptic drugs in critically ill patients.Critical care (London, England) · 2018Review
- Renal replacement therapy in patients with acute respiratory distress syndrome: a single-center retrospective study.International journal of nephrology and renovascular disease · 2018Article
- Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies.Critical care research and practice · 2016Article
- Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.Clinical pharmacokinetics · 2015Review
- Dosing nucleoside reverse transcriptase inhibitors in adults receiving continuous veno-venous hemofiltration.Clinical drug investigation · 2015Article
- Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Antimicrobial agents and chemotherapy · 2011Article
- Antibiotic dosing in critically ill patients with acute kidney injury.Nature reviews. Nephrology · 2011Review
- Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.The Canadian journal of hospital pharmacy · 2010Article
- Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.The Annals of pharmacotherapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advantages of continuous haemofiltration and haemodialysis over intermittent haemodialysis for the treatment of acute renal failure are well recognised. In intensive care patients, 4 different continuous procedures, arteriovenous and venovenous haemofiltration (CAVH and CVVH) or haemodialysis (CAVHD and CVVHD), are employed. These effective detoxification treatments require knowledge of their influence on drug disposition. Data on kinetics of drugs during continuous treatment are scarce and limited almost exclusively to the oldest and least effective procedure (CAVH). Selected dialysis membranes may adsorb drugs, as in the case of aminoglycosides. In addition, elimination of substances with large molecular weights may vary depending on the pore size of the membrane, as in the case of vancomycin. Thus, even if drug dosages can be based on pharmacokinetic studies, selection of a dialysis membrane not studied may cause unpredictable drug concentrations. With these limitations in mind and considering the available literature on pharmacokinetics in patients with renal failure, general guidelines for drug dosage during continuous renal replacement therapy can be given. In haemofiltration, drug protein binding is the major factor determining sieving, i.e. the appearance of the drug in the ultrafiltrate. In haemodialysis, diffusion is added to ultrafiltration, and therefore the saturation of the combined dialysate and ultrafiltrate will decrease further with increasing dialysate flow rate. In continuous haemofiltration or haemodialysis the extracorporeal clearance can be calculated by multiplying the saturation value (estimated or, better, measured) with the ultrafiltrate and dialysate flow rate. Dividing the extracorporeal clearance by the total clearance (including the nonrenal clearance) gives the fraction of the dose removed due to extracorporeal elimination. Whether dosage recommendations available for anuric patients have to be modified or not can be decided on the basis of this value. In case of high nonrenal clearance, the degree of saturation is without clinical significance. Based on these considerations guidelines have been constructed for the effect of extracorporeal elimination on more than 120 different drugs commonly used in intensive care patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.